Since so many people are concerned about retaining lean mass, I thought that this article might be interesting.
At a conference in Turkey earlier this month, the phase 3a REDEFINE results were released and suggest an actual increase of 12% in the lean mass proportion for the cagrisema group. Of course, total lean mass decreased in absolute terms, but since more fat mass was lost, the % of lean mass proportionally increased.
These results are positive for those considering one of the amylin analogues as part of the strategy.
ECO 2026: REDEFINE-1 demonstrates CagriSema's improvement in body composition - Pharmaceutical Technology
Data from the REDEFINE-1 trial (NCT05567796) were recently presented in Türkiye, assessing Novo Nordisk's CagriSema in adults with obesity.
www.pharmaceutical-technology.com
At a conference in Turkey earlier this month, the phase 3a REDEFINE results were released and suggest an actual increase of 12% in the lean mass proportion for the cagrisema group. Of course, total lean mass decreased in absolute terms, but since more fat mass was lost, the % of lean mass proportionally increased.
These results are positive for those considering one of the amylin analogues as part of the strategy.
ECO 2026: REDEFINE-1 demonstrates CagriSema's improvement in body composition - Pharmaceutical Technology
Data from the REDEFINE-1 trial (NCT05567796) were recently presented in Türkiye, assessing Novo Nordisk's CagriSema in adults with obesity.
www.pharmaceutical-technology.com
